Obstructive sleep apnoea (OSA) is a progressive disorder characterised by repeated upper-airway collapse during sleep that leads to intermittent hypoxia and hypercapnia, fragmented sleep, fluctuations in blood pressure and increased sympathetic nervous system activity [1] . Population studies in the early 1990s found OSA (defined by an apnoea-hypopnoea index (AHI) >5 events·h −1 ) in 9% of middle-aged women and 24% of middle-aged men [2] . Later studies have demonstrated a higher occurrence (in 17% of women and 34% of men), which was mainly attributed to increasing body mass index in the general population over time [3] . Notably, the HypnoLaus study, which is to date the largest European epidemiological study [4] , demonstrated that 61% of women and 84% of men in an unselected general cohort of 2121 adults had OSA based on the polysomnographic AHI cut-off level of 5 events·h −1 and on the recent hypopnoea definitions of the American Academy of Sleep Medicine [5] . HEINZER et al. [4] concluded in the HypnoLaus study that the prevalence of OSA was highly dependent on technical procedures (i.e. nasal cannula recording subtle breathing variation for scoring hypopnoeas) as well as the hypopnoea definition (3% desaturations instead of 4% desaturations, and/or arousals) [5] . There have been significant changes in the definition of OSA over time, with research reports suggesting an independent association between OSA and metabolic and cardiovascular disease (CVD), especially in the sleep clinic cohorts with self-reported excessive daytime sleepiness (EDS) [6] [7] [8] . The first choice for treatment of OSA is positive airway pressure (PAP), which has been demonstrated to reduce EDS and improve the quality of life [9] . In patients with CVD who do not report EDS, adherence to PAP treatment has been challenging in the recent randomised controlled trials (RCTs) [10, 11] . It has been shown that OSA has different clinical phenotypes based on anatomical [12] or physiological [13] features, or a mixture of both [14] . The degree of EDS, sex differences in presentation of symptoms and comorbid conditions may vary substantially [15] . OSA during rapid eye movement sleep has been linked to hypertension among individuals who otherwise have normal total AHI values [16] , suggesting that this subgroup of patients deserve attention with regard to CVD outcomes [17] . Despite increasing research evidence linking OSA with metabolic and cardiovascular outcomes, and the beneficial effect of PAP treatment in the observational studies [8, 18] , there is still a lack of convincing data from the RCTs that treating this disorder reduces the cardiovascular risk. Ethical concerns regarding randomisation of symptomatic OSA patients to no treatment have influenced the design of long-term RCTs during the last decade, focusing on asymptomatic or minimally
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In this issue of the European Respiratory Journal, RANDERATH et al. [23] report from an ad hoc working group of the Sleep Disordered Breathing Group of the European Respiratory Society and the European Sleep Research Society, who convened a consensus conference examining the current state of knowledge related to the diagnosis and treatment of OSA based on what were determined to be the most relevant publications in the previous 5 years. The current challenges in the field were discussed and topics were identified for future research: epidemiology, phenotyping, underlying mechanisms, prognostic implications, and optimal treatment of patients with OSA. RANDERATH et al. [23] concluded that a revision to the diagnostic criteria for OSA was required, to include factors that reflect different clinical and pathophysiological phenotypes, and relevant comorbidities such as nondipping nocturnal blood pressure. The group further concluded that current OSA severity thresholds should also be revised to reflect factors such as disparity in AHI between polysomnography and home sleep apnoea testing that does not include sleep stage measurements, in addition to the poor correlation between AHI and EDS. The authors also suggested that the management decisions should be linked to the underlying clinical and pathophysiological phenotyping, addressing outcomes beyond the AHI.
RANDERATH et al. [23] should be commended for examining the important gaps of knowledge and exploring future opportunities for research and management of patients with OSA. In brief, 19 experts from 11 European countries, representing a spectrum of specialists in pulmonary medicine, neurology and psychiatry, in addition to basic and translational scientists, defined eight major topics: clinical phenotyping of OSA, assessment of disease severity, diagnostic algorithms/new tools, EDS and related driving risk, OSA and neuro-psychiatric disorders, outcomes of OSA, comorbid conditions in OSA, and optimum treatment. The report was based on the relevant papers on each respective topic during the previous 5 years, and the working subgroups were tasked to describe the most important clinical challenges and research priorities in the field of OSA for the next 5-10 years. The findings of the subgroup discussions were adjudicated by the participants utilising a Delphi consensus approach.
Regarding clinical phenotyping of OSA, the need for an individualised approach was identified. Conventional diagnostic procedures, pathophysiological phenotypes, clinical phenotypes and the assessment of target organ consequences were reviewed. Priorities for future research included redefining the role of polysomnography, addressing the clinical importance of the pathophysiological traits, cluster analysis in prospective clinical cohorts and translation of the OSA subtypes into personalised medicine [23] . As highlighted in another recent review [24] , a unique objective index such as the AHI for the classification of the OSA severity does not consistently resolve the problem of patient classification and treatment selection. Using the Epworth Sleepiness Scale, a subjective measure, to evaluate one of the main symptoms of OSA, is imprecise. A molecular signature for EDS is needed in clinical practice and would be particularly useful in determining fitness to drive [23] . Some repetition is understandable in categorising the challenges and perspectives for the eight topics, primarily related to overlap. This project reflects the challenge of bringing experts from different European countries and disciplines together to achieve consensus regarding the diagnosis and clinical management of OSA patients. The consensus-based approach employing heterogeneous ad hoc working subgroups provides a unique perspective regarding personalised diagnostic and therapeutic approaches to OSA management. Other topics overlapping with sleep disordered breathing, such as central sleep apnoea (CSA) with Cheyne-Stokes respiration as well as hypoventilation, were excluded from the review, although shifting from OSA to CSA and vice versa is frequently observed in cardiovascular cohorts. The future perspectives frequently posed questions rather than solutions. Of note, one recent relevant paper that was not included among the reviewed references is worth mentioning [25] . This report provided a contextual framework for interpreting the results of recent studies, key clinical messages, and suggestions for future sleep and cardiovascular research [25] . As stated in the current article by RANDERATH et al. [23] , as well as in other recent reviews [24, 26] , future perspectives should consider individual risk factors, incorporate new multimodality treatments that also address adherence, and consider implementation of trials that are appropriately powered to target end-points and to support subgroup analyses. Strengthening collaboration among the cardiology, sleep medicine and clinical trial specialists would be beneficial [25] . These perspectives also reaffirm the concept of P4 medicine as a roadmap for improving care in OSA that is personalised, predictive, preventive and participatory in nature [27] . advisory fees from ResMed and Inspire Medical Systems; and personal advisory fees from Emmi Solutions, Jazz Pharmaceuticals, Itamar Medical and Seperation Design Group, outside the submitted work.
